ATMI — Q4 2012 Earnings Presentation
17 slides from ATMI's earnings presentation, Feb 6, 2013
Slide 1: Q4 2012 Earnings Teleconference
Q4 2012 Earnings Teleconference February 6, 2013
Slide 2: Safe Harbor Statement
Safe Harbor Statement Statements contained herein that relate to ATMI's future performance, including, without limitation, statements with respect to ATMI’s anticipated results of operations or level of business for 2013 or any other future period, are forward-looking statements within the safe harb
Slide 3: Q4 2012 Summary
Q4 2012 Summary > Revenues and net income grew Y/Y > Incremental SDS contribution > LifeSciences demand growth > Negative factors: weaker wafer start environment, pricing pressure and inventory management by some of our customers > Continued strong cash generation > Progress on growth initiatives >
Slide 4: ATMI Q4 2012 financial results
ATMI $M (except per share data) Q42012 Q42011 Change Revenue 100.1 90.3 11% Gross profit 48.8 42.5 15% Gross margin 19% 47% Operating income (loss) 15.5 (76.6) NM Operating margin 16% (85%) Net income (loss) 12.6 (47.2) NM EPS. $0.39 ($1.49) Q3 2012 Change 108.8 (8%) 54.4 (10%) 50% 20.5 (24%) 19% 14
Slide 5: Diverse Revenue Mix
Diverse Revenue Mix Q4 2012 Revenues by Product mimplant 26% ™Cu Materials 45% m= NOWPak 13%, mlifeSciences 11% Other 5% Q4 2012 Revenues by Sector mLogic 59% ™ Memory 22% = Display 8% sLifeSciences 11% @4 2012 Revenues by Geography mAsia 71% = North America 18% m Europe 11% Implant growth from SDS
Slide 6: Microelectronics
Microelectronics Q42012 Q42011 Change Q32012 Change Revenues 89.1 81.1 10% 98.5 (10%) Gross margin 50% 48% 52% Operating income (loss) 23.4 (63.8) NM 34.4 (32%) Operating margin 26% -79% 35% > Revenues grew Y/Y as SDS incremental contribution offset weaker wafer starts, customer material efficiency
Slide 7: LifeSciences
LifeSciences Q42012 Q42011 Change Q32012 Change Revenues 10.9 9.1 20% 10.4 5% Gross margin 38% 35% 28% Operating income (loss) 13 (1.4) (2.1) Operating margin 12% (15%) (21%) > Revenues up Y/Y on increased demand > Operating income in Q4 2012 includes $2.4M benefit for earnout adjustment related to
Slide 8: Other Financial Data
Other Financial Data Q4 2012 Q4 2011 Q3 2012 Cash and marketable securities 168.5 113.5 139.3 Cash from operating activities 39.8 (86.0) 20.3 Capital Expenditures 10.9 6.5 5.2 Depreciation & Amortization 7.4 6.9 6.9 Headcount 817 815 825 > Strong cash balance and flexible balance sheet to invest in
Slide 9: Outlook
Vv Outlook Microelectronics > Wafer starts seasonally flat to slightly down sequentially in Q1 2013; full-year 2013 wafer starts up 3-5% > Margin improvement through volume benefit and lower R&D spending LifeSciences > Confident in our long-term revenue CAGR of 20-30% > GM improving through volume b
Slide 10: Capabilities to deliver Process Efficiency
Capabilities to deliver Process Efficiency * Interfacial science and analytical capability * Molecular creation and formulation * Process expertise * Technology roadmap management Technical Depth lobal * Worldwide developmental capability Globa : : * Comprehensive supply chain excellence Infrastruct
Slide 11: Technology aligned with end market growth trends
Technology aligned with end market growth trends Mobility demands and performance gains in advanced electronics Affordable health care for emerging markets Sustainable solutions to address resource challenges u & ATMI
Slide 12: Clear long-term financial targets
Clear long-term financial targets * Microelectronics growth rate greater than wafer starts Revenues * LifeSciences growing 20-30% CAGR over next several years * Gross margins >50% for each segment * Operating margins >20% * LifeSciences operating profit on a quarterly basis by end of 2013 Profitabil
Slide 13: Thank you for your interest
@O ATM! Thank you for your interest. Troy Dewor Director, Investor Relations 203.207.9349 [email protected]
Slide 14: Appendix
Appendix
Slide 15: ATMI — a technology company enabling Process Efficiency gains
ATMI —a technology company enabling Process Efficiency gains for our customers Revenues ($M) > Diverse Technology Portfolio > >1,000 patents granted since $367 $390 $407 founding > Formulated and synthesized materials il [_ {] > High-integrity material delivery and / 9040 ‘ oT : Sit ‘ processing sys
Slide 16: Microelectronics — enabling technology for semiconductor manufacturing
Microelectronics — enabling technology for semiconductor manufacturing Revenues ($M) > Innovative materials and material $336 $351 $366 delivery systems for semiconductor and flat panel display [] [| > Improving profitability through SDS r T , 1 Direct and new product introductions 2010 2011 2012 >
Slide 17: LifeSciences — single-use technology partner
LifeSciences — single-use technology partner Revenues ($M) > Serving critical and cutting-edge life science applications $38 $42 4 > Enables product development life cycle | optimization > Creates entirely new market segment v 2010 2011 2012 | > Nearing growth inflection point Operating Income (Loss